Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice

Digestive Diseases and Sciences

Volumn 58, Issue 1, 2013, Pages 209-215

  Patil, Seema A ^a   Rustgi, Ankur ^a   Langenberg, Patricia ^a   Cross, Raymond K ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Veterans Affairs   (United States)

Author keywords

Adalimumab; Anti TNF therapy; Certolizumab pegol; Crohn's disease; Infliximab

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; COMPARATIVE EFFECTIVENESS; CROHN DISEASE; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; RETROSPECTIVE STUDY; SCORING SYSTEM; TERTIARY HEALTH CARE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MIDDLE AGED; POLYETHYLENE GLYCOLS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84873129604     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2323-0     Document Type: Article

References (17)

1. Van Deventer SJH. Tumor necrosis factor and Crohn's disease. Gut. 1997;40:443-448.
2. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohns disease cA2 study group. N Engl J Med. 1997;337:1029-1035.
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
4. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
5. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
6. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333.
7. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
8. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829-838.
9. Nesbitt A, Fossatti G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13:1323-1332.
10. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357:228-238.
11. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239-250.
12. Lichtenstein G, Thomsen O, et al. Long-term remission with Certolizumab Pegol in Crohn's disease over 3.5 Years: results from the PRECiSE 3 study. Am J Gastroenterol. 2009;104:S450.
13. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
14. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009;137:1628-1640.
15. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel diseases: controversies, consensus, and implications. Gut. 2006;55:749-753.
16. Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol. 2010;8:357-363.
17. Jowett SL, Seal CJ, Barton JR, et al. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am J Gastroenterol. 2001;96:2921-2928.